A new monoclonal antibody treats severe asthma / Diane S. Aschenbrenner
Series: American Journal of Nursing. 116 : 7, page 24-25 Publication details: July 2016.Content type:- text.
- unmediated.
- volume.
- 0002-936X
Current library | Call number | Status | Date due | Barcode |
---|---|---|---|---|
Manila Tytana Colleges Library REFERENCE SECTION | Not For Loan |
* Reslizumab (Cinqair), a new human monoclonal antibody, has been approved to treat severe asthma in adults. Given intravenously, the drug is used as adjunct therapy, in conjunction with inhaled corticosteroids, to reduce the frequency of asthma exacerbations, relieve asthma symptoms, and improve lung function in patients with elevated blood eosinophil levels. * Like all monoclonal antibodies, it carries a risk of anaphylaxis.
Nursing
There are no comments on this title.